ESR1 and breast carcinoma: Somatic failure to activate ATM/CHK2, through loss of upstream DNA repair signaling, such as the MutL complex of the mismatch repair pathway, in ER+/HER2− breast cancer also induces resistance to standard endocrine therapies (26–28).